Stocktoria
NRC HEALTH NRC
Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 1997-10-01
NRC HEALTH financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $137.4M | $143.1M | $148.6M | $151.6M | $148.0M | $133.3M | $128.0M | $119.7M | $117.6M | $109.4M |
| SG&A expense | $54.8M | $44.9M | $46.6M | $42.7M | $39.0M | $34.4M | $33.0M | $31.4M | $29.7M | $28.4M |
| Operating income | $22.6M | $35.2M | $40.0M | $46.5M | $50.3M | $42.7M | $43.0M | $35.3M | $34.2M | $31.2M |
| Interest expense | — | $2.6M | $862,000 | $1.2M | $1.7M | $1.8M | $2.1M | $1.5M | $82,000 | $190,000 |
| Income tax | $6.2M | $7.9M | $9.0M | $11.0M | $11.2M | $4.2M | $8.1M | $4.7M | $11.3M | $10.8M |
| Net income | — | — | — | — | — | — | — | $30.0M | $22.9M | $20.5M |
| EPS (diluted) | $50.00 | $1.04 | $1.25 | $1.27 | $1.46 | $1.45 | $1.26 | — | — | — |
| Operating cash flow | $26.4M | $34.6M | $38.1M | $36.3M | $46.3M | $40.6M | $40.9M | $39.8M | $28.1M | $26.8M |
| Free cash flow | $15.7M | $19.2M | $22.3M | $26.4M | $40.8M | $36.7M | $36.3M | $33.9M | $23.5M | $22.9M |
| Cash & equivalents | $4.1M | $4.2M | $6.7M | $25.0M | $54.4M | $34.7M | $13.5M | $13.0M | $34.7M | $33.0M |
| Total assets | $134.9M | $132.5M | $122.4M | $130.5M | $157.5M | $133.4M | $110.7M | $108.0M | $127.3M | $120.6M |
| Total liabilities | $120.9M | $101.3M | $73.5M | $58.4M | $72.2M | $69.1M | $77.8M | $88.9M | $37.3M | $37.8M |
| Shareholders' equity | $14.0M | $31.3M | $49.0M | $72.0M | $85.3M | $64.3M | $32.9M | $19.1M | $90.0M | $82.8M |
Growth · year-over-year · Revenue CAGR 2.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -4.0% | -3.7% | -2.0% | +2.4% | +11.0% | +4.1% | +6.9% | +1.8% | +7.5% | +6.9% |
| Net income growth | — | — | — | — | — | — | — | +31.0% | +11.8% | +16.5% |
| EPS growth | +4707.7% | -16.8% | -1.6% | -13.0% | +0.7% | +15.1% | — | — | — | — |
| Free cash flow growth | -17.9% | -14.1% | -15.5% | -35.3% | +11.4% | +1.1% | +7.0% | +44.0% | +2.9% | +20.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.